Testosterone cypionate — Listed as containing the long-acting cypionate ester of testosterone.

250 mg/ml listed concentration — Expresses the stated amount of testosterone cypionate per millilitre of solution, not a recommended dose.

Oil-based injectable formulation — Described in the product information as an oil-based preparation.

Prolonged-release ester — Testosterone cypionate is absorbed slowly from oil-based intramuscular formulations, supporting a prolonged duration of action.

What is UPA Test C 250?

UPA Test C 250 is listed as an oil-based injectable formulation containing testosterone cypionate at a concentration of 250 mg/ml.

What does 250 mg/ml mean?

It describes the listed concentration: 250 milligrams of testosterone cypionate per millilitre of solution. This is not a recommended dose or a statement of the total amount in the container.

What is testosterone cypionate?

Testosterone cypionate is a long-acting ester of testosterone. The ester allows testosterone to be released gradually after administration.

Is this a general wellness or muscle-building supplement?

No. Testosterone cypionate is a hormone medicine, not a general wellness supplement. It should not be used for self-directed bodybuilding or performance enhancement.

Can I choose a dose from the product concentration?

No. Concentration alone cannot determine an appropriate dose. Medical use requires an individual assessment, a prescription where required, and monitoring by a qualified healthcare professional. Do not self-prescribe or adjust treatment based on this listing.

Can testosterone cypionate cause side effects or affect fertility?

Yes. Testosterone therapy can cause adverse effects and suppress sperm production. Discuss fertility plans, existing medical conditions and other medicines with a qualified healthcare professional before considering treatment.

Testosterone Cypionate: Research and Clinical References

The references below describe testosterone cypionate and testosterone therapy generally. They are not studies of UPA Test C 250 and do not verify this product’s identity, concentration, sterility, quality or clinical effectiveness.

Pharmacology and duration of action

Published prescribing information describes slow absorption of oil-based testosterone cypionate after intramuscular administration and an approximate eight-day half-life. These pharmacokinetic properties explain its prolonged action; they are not instructions for choosing a dose or injection schedule.

Read: DailyMed — Testosterone Cypionate prescribing information

Clinical evidence and appropriate patient selection

The Endocrine Society’s 2018 clinical practice guideline recommends diagnosing hypogonadism only when compatible symptoms and signs occur alongside unequivocally and consistently low testosterone concentrations. Its accompanying summary emphasises confirmation of laboratory results and individual assessment rather than treating a single low reading.

Read: Endocrine Society — Testosterone Therapy for Hypogonadism guideline

Hormonal feedback and fertility considerations

The DailyMed prescribing information explains that externally administered androgens inhibit the body’s own testosterone release through hormonal feedback. It also describes suppression of sperm production at large doses. Testosterone should not be treated as a fertility-enhancing supplement.

Read: DailyMed — Clinical pharmacology and hormonal feedback

Interpreting the evidence

Clinical findings for diagnosed hypogonadism should not be interpreted as evidence supporting self-directed bodybuilding, performance enhancement or routine treatment of otherwise healthy individuals. The Endocrine Society stresses appropriate diagnostic assessment and monitoring.

Read: Endocrine Society — Recommendations to improve testosterone prescribing practices